Roche reports continued strong demand across portfolio in H1 2022

The Swiss pharmaceutical firm has just published its financial figures for the first half of 2022, noting among other things that hemophilia drug Hemlibra has performed well year to date.

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

Swiss pharmaceutical group Roche experienced continued strong demand for its drugs and Covid-19 tests in the first half of the year, according to a Thursday press release announcing the company’s figures for the first six months of 2022.

Roche’s pharmaceutical division increased sales 3% to CHF 22.3bn from CHF 21.7bn in the same period in 2021 (USD 22.9bn from USD 22.3bn). Hemlibra, the company’s treatment for rare blood disease hemophilia, and a competitor of Danish Novo Nordisk’s drug Novoseven, was behind some of the advance bringing in CHF 1.8bn (USD 1.9bn), corresponding to growth of 30%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs